Biblio
“Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex.”, J Alzheimers Dis, vol. 61, no. 2, pp. 653-662, 2018.
, “Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1589-1598, 2018.
, “The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 98, no. 1, pp. 13-32, 2024.
, “Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings.”, J Alzheimers Dis, vol. 94, no. 1, pp. 217-226, 2023.
, “Automatic Subtyping of Individuals with Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1185-1194, 2021.
, “Avoiding Over-Reliance on Multi-Domain Interventions for Dementia Prevention.”, J Alzheimers Dis, vol. 90, no. 3, pp. 989-992, 2022.
, “Awareness of the COVID-19 Outbreak and Resultant Depressive Tendencies in Patients with Severe Alzheimer's Disease.”, J Alzheimers Dis, vol. 77, no. 2, pp. 539-541, 2020.
, “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
, “BACE1 Inhibitors for Alzheimer's Disease: Current Challenges and Future Perspectives.”, J Alzheimers Dis, vol. 101, no. s1, pp. S53-S78, 2024.
, “BACE2: A Promising Neuroprotective Candidate for Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S159-S171, 2023.
, “Barriers to Effective Memory Assessments for Alzheimer's Disease.”, J Alzheimers Dis, vol. 90, no. 3, pp. 981-988, 2022.
, “Behavioral and Psychological Symptoms of Dementia in Different Dementia Disorders: A Large-Scale Study of 10,000 Individuals.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1307-1318, 2022.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1505-1527, 2021.
, “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.
, “Best Medicine for Dementia: The Life-Long Defense of the Brain.”, J Alzheimers Dis, vol. 94, no. 1, pp. 51-66, 2023.
, “Better Subjective Sleep Quality Partly Explains the Association Between Self-Reported Physical Activity and Better Cognitive Function.”, J Alzheimers Dis, vol. 87, no. 2, pp. 919-931, 2022.
, “Biallelic Loss of Function of SORL1 in an Early Onset Alzheimer's Disease Patient.”, J Alzheimers Dis, vol. 62, no. 2, pp. 821-831, 2018.
, “Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 84, no. 2, pp. 461-477, 2021.
, “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.
, “Biological Factors Contributing to the Response to Cognitive Training in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 1, pp. 333-345, 2018.
, “Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis.”, J Alzheimers Dis, vol. 50, no. 1, pp. 161-74, 2016.
, “Blood Pressure Variability and Plasma Alzheimer's Disease Biomarkers in the SPRINT Trial.”, J Alzheimers Dis, vol. 97, no. 4, pp. 1851-1860, 2024.
, “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
, “Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis.”, J Alzheimers Dis, vol. 79, no. 1, pp. 177-195, 2021.
,